 VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75 over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare Bio Boom speculative portfolio. The companys efforts in 2022 have fortified that position. 